Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term bone-marrow transplantation. Found 16 abstracts

Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F. Multiple Myeloma. Journal of the National Comprehensive Cancer Network. 2011 Oct;9(10):1146-83.   PMCID: not NIH funded
Tsai DE, Aqui NA, Tomaszewski JE, Olthoff KM, Ahya VN, Kotloff RM, Bloom RD, Brozena SC, Hodinka RL, Stadtmauer EA, Schuster SJ, Nasta SD, Porter DL, Luger SM, Klumpp TR. Serum protein electrophoresis abnormalities in adult solid organ transplant patients with post-transplant lymphoproliferative disorder. Clinical transplantation. 2005 Oct;19(5):644-52.
Smith MR, Jin F, Joshi I. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts. Molecular Cancer Therapeutics. 2004 Dec;3(12):1693-9.
Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. New England Journal of Medicine. 2000 Apr 13;342(15):1069-76.
Visonneau S, Cesano A, Porter DL, Luger SL, Schuchter L, Kamoun M, Torosian MH, Duffy K, Sickles C, Stadtmauer EA, Santoli D. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clinical Cancer Research. 2000 May;6(5):1744-54.
Meropol NJ, Rustum YM, Creaven PJ, Blumenson LE, Frank C. Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: A potential role for growth factor as mucosal protectant. Cancer Investigation. 1999 Jan;17(1):1-9.
Schilder RJ, Johnson S, Gallo J, Kindsfather S, Rogers B, Bookman MA, Millenson MM, Boente M, Rosenblum N, Litwin S, Ozols RF. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. Journal of Clinical Oncology. 1999 Jul;17(7):2198-207.
Schilder RJ, Shea TC. Multiple cycles of high-dose chemotherapy for ovarian cancer. Seminars in Oncology. 1998 Jun;25(3):349-55.
Movsas B, Raffin TA, Epstein AH, Link CJ. Pulmonary radiation injury. Chest. 1997 Apr;111(4):1061-76.
Smith MR. Non-Hodgkin's lymphoma. Current Problems in Cancer. 1996 Jan;20(1):6-77.
Kaul S, Igwemezie LN, Stewart DJ, Fields SZ, Kosty M, Levithan N, Bukowski R, Gandara D, Goss G, Odwyer P, Schacter LP, Barbhaiya RH. Pharmacokinetics and Bioequivalence of Etoposide Following Intravenous Administration of Etoposide Phosphate and Etoposide in Patients with Solid Tumors. Journal of Clinical Oncology. 1995 Nov;13(11):2835-41.
Kotz KW, Schilder RJ. High-Dose Chemotherapy and Hematopoietic Progenitor-Cell Support for Patients with Epithelial Ovarian-Cancer. Seminars in Oncology. 1995 Jun;22(3):250-62.
Krigel RL, Palackdharry CS, Padavic K, Haas N, Kilpatrick D, Langer C, Comis R. Ifosfamide, Carboplatin, and Etoposide Plus Granulocyte- Macrophage Colony-Stimulating Factor - a Phase-I Study with Apparent Activity in Non-Small-Cell Lung-Cancer. Journal of Clinical Oncology. 1994 Jun;12(6):1251-8.
Walker F, Roethke SK, Martin G. An Overview of the Rationale, Process, and Nursing Implications of Peripheral-Blood Stem-Cell Transplantation. Cancer nursing. 1994 Apr;17(2):141-8.
Devries EG, Hamilton TC, Lind M, Dauplat J, Neijt JP, Ozols RF. Drug-Resistance, Supportive Care and Dose Intensity. Annals of Oncology. 1993 Jan;4:57-62.
Young RC. Etoposide in the Treatment of Non-Hodgkins-Lymphomas. Seminars in Oncology. 1992 Dec;19(6):19-25.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term bone-marrow transplantation

bone-marrow transplantation colony-stimulating factor carboplatin therapy cyclophosphamide support chemotherapy solid randomized trial high-dose therapy solid tumors intensive therapy tumors neutropenia carcinoma epstein-barr-virus large-cell lymphoma phase-i gynecologic-oncology-group disease thoracic irradiation mantle-field hematopoietic rescue combination chemotherapy cells diarrhea oral mucositis chronic lymphocytic- radiation- donor lymphocyte infusions rescue Waldenstrom's monoclonal protein radiation pneumonitis rat lung immunodeficient scid mice high-dose cyclophosphamide blood progenitor cells pharmacodynamics platinum cyclophosphamide chemotherapy histiocytic lymphoma apheresis vp-16-213 diffuse low-grade lymphoma consolidation therapy combination breast-cancer novel therapies patient adjuvant therapy term follow-up cytogenetics monoclonal gammopathy total-body irradiation stage-iii thiotepa t(14-18) chromosomal translocation breast-cancer patients elderly patients supportive therapies pulmonary fibrosis selection aggressive lymphomas stem cell follicular lymphoma therapy oncology group rates high-dose chemotherapy paclitaxel hodgkins-disease supportive care invivo stem-cell transplantation thalidomide plus calcium leucovorin acute-leukemia cancer remission leukemia bisphosphonates high response chop chemotherapy myelosuppression refractory ovarian- organ transplantation serum protein electrophoresis proteasome inhibitor drug resistance primary amyloidosis progenitor cells long-term undetermined significance immunosuppression follow-up line tall-104 s-transferase activity southwest-oncology-group ovarian cancer ovarian-cancer 5-fluorouracil randomized hematopoietic reconstitution 2004 nseca r-cancer res-v64-p1546 post-transplant lymphoproliferative disorder fluorouracil activated killer-cells NCCN Guidelines growth-factor-beta immunomodulatory drugs peripheral-blood regimen recombinant chronic lymphocytic-leukemia GM-CSF granulocyte-macrophage colony-stimulating central-nervous-system interleukin-2 pegylated liposomal doxorubicin dexamethasone 2011 carthy p-haematologica-v96-ps23 poor-prognosis recipients intensive chemotherapy line wsu-fsccl immunoglobulin fusion transcript newly-diagnosed myeloma 2009 carthy pl-blood-v114 high-dose NCCN Clinical Practice Guidelines stem cell transplant morbidity recovery lymphocytes reactions interleukin-2 receptors topoisomerase-i inhibitors positron-emission-tomography transplantation high-dose ifosfamide C-reactive protein autologous blood combined modality therapy cell lung-cancer phase-i-ii radiation non-Hodgkin's lymphoma soluble diffuse histiocytic lymphoma multiple myeloma
Last updated on Wednesday, February 05, 2020